31 October 2013
Immunocore initiates Phase IIa clinical trial for IMCgp100 in melanoma
Immunocore today announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.
Please click on the link below to download the full Press Release: